At CPC Scientific, quality, innovation, and sustainability drive everything we do. We recently sat down with Chief Solutions Officer Baosheng Liu, PhD to discuss how CPC Scientific ensures the highest standards in peptide and oligonucleotide manufacturing, and how the CDMO industry is evolving in the next decade.

When asked how CPC Scientific ensures quality, Dr. Liu explains that quality is embedded into every step of operations. From following strict GMP guidelines and rigorous in-process controls to heavy investment in staff training, quality is treated as a cultural foundation. Every batch undergoes thorough review by a dedicated QA unit, supported by advanced analytical technologies that confirm purity, sequence integrity, and compliance with client specifications.

With one of the broadest portfolios of solid- and liquid-phase synthesis capabilities in the industry, CPC Scientific has built a reputation for handling projects that others may decline.

Our ability to deliver at scale is reinforced by the cross-functional collaboration behind the scenes. Production, R&D, and QA experts regularly work side-by-side to troubleshoot complex syntheses together, reflecting how deep technical expertise and close teamwork remain indispensable in modern GMP manufacturing.

“Clients come to us because we can manage complexity while scaling efficiently from discovery batches to large-scale GMP campaigns,” Dr. Liu says.

What ultimately makes this possible, he notes, is a company-wide culture rooted in curiosity, accountability, and collaboration. Through ongoing training as well as continuously empowering staff to contribute improvements, CPC Scientific fosters an environment where our team members are proud to work together and take collective ownership of quality and innovation at every level. This ethos is mirrored in how we manage our client projects: as shared endeavors and true partnerships.

CPC Scientific pairs our integrated teamwork model with innovative manufacturing technology to accelerate results. Continuous monitoring and digital project tracking have increased speed, safety, and transparency.

Our recent and upcoming facility upgrades, including larger reactors, high-resolution mass spectrometry, and UPLC systems, are scaling annual production capacity into the tons, enabling even faster turnaround times for clients worldwide.

Dr. Liu emphasizes that sustainability goes beyond just compliance; it’s also an opportunity for innovation. CPC Scientific has introduced solvent recycling programs, invested in energy-efficient equipment, and optimized synthesis to cut solvent use. According to Dr. Liu, the balance is maintaining strict GMP standards while validating greener processes. For clients, these efforts reduce environmental impact while often improving cost efficiency.

Explore our white papers on green chemistry to see some of our innovative sustainability measures in action.

Looking to the next decade, Dr. Liu highlights personalized medicine, peptide–drug conjugates, and sustainability as key trends shaping the CDMO industry. Perhaps most pressing, he adds, is scale-up capacity, especially as demand for GLP-1 medications continues to surge.

To meet future demand, CPC Scientific is expanding its capacity and strengthening its global supply chain. A cornerstone of this effort is our new Rocklin, California facility, scheduled to open in 2026, further reinforcing our commitment to scale, quality, and sustainability.

“If there’s one thing I want clients to know,” Dr. Liu concludes, “it’s that we combine deep scientific expertise with practical, client-focused solutions. Our mission is to turn innovative science into reliable, scalable products that improve lives, while maintaining the highest standards of quality and sustainability.”